Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.71 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.71 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | IDO1 | P14902 | 1/20 | 0.59 |
| ▸ | PPARD | Q03181 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6440989 | 0.98 | FFAR1 (0.69) | FFAR1FFAR4KEAP1IDO1PPARD | |
| Trifluoroacetic Acid SCHEMBL27529274 | 0.90 | FFAR1 (0.61) | FFAR1FFAR4KEAP1IDO1PPARD | |
| SCHEMBL30990549 | 0.89 | FFAR1 (0.59) | FFAR1FFAR4KEAP1IDO1PPARD | |
| SCHEMBL69746 | 0.88 | FFAR1 (0.81) | FFAR1FFAR4KEAP1CA1CA2 | |
| SCHEMBL1857558 | 0.87 | HDAC1 (0.67) | FFAR1FFAR4IDO1ALDH1A1MAPT | |
| SCHEMBL29018552 | 0.86 | FFAR1 (0.59) | FFAR1FFAR4KEAP1IDO1PPARD | |
| SCHEMBL29018554 | 0.86 | FFAR1 (0.59) | FFAR1FFAR4KEAP1IDO1PPARD | |
| Hydrochloric Acid SCHEMBL25264643 | 0.85 | FFAR1 (0.77) | FFAR1FFAR4KEAP1CA1CA2 | |
| SCHEMBL1114650 | 0.85 | MAPT (0.66) | FFAR1FFAR4MAPTHSD17B10RXFP1 | |
| Hydrochloric Acid SCHEMBL3866368 | 0.85 | SMN1; SMN2 (0.64) | FFAR1FFAR4IDO1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 753 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137643-A | Composite material, preparation method thereof, photoelectric device and display device | 广东聚华新型显示研究院 | 2025-06-13 | — | — | CN | claimed |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2025-05-20 | — | — | US | claimed |
| CN-118496175-A | TRADD inhibitor derivative and preparation method and application thereof | 安徽医科大学 | 2024-08-16 | — | — | CN | claimed |
| US-20220194909-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2022-06-23 | — | — | US | claimed |
| WO-2020210922-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11Β-HSD1) | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2020-10-22 | — | — | WO | claimed |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-13 | — | — | US | claimed |
| CN-1201454-A | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 1998-12-09 | — | — | CN | claimed |
| CN-122054798-A | Perovskite absorption layer, perovskite/silicon laminated solar cell and preparation method thereof | 宣城先进光伏技术有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025128805-A1 | A CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-120137643-A | Composite material, preparation method thereof, photoelectric device and display device | 广东聚华新型显示研究院 | 2025-06-13 | — | — | CN | disclosed |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) | 2025-05-20 | — | — | US | disclosed |
| US-4885153-A | Radiohalogenated for proteins | NEORX CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| US-RE32944-E | Aromatic carboxylic amide derivatives | Kissei Yakuhin Kogyo Kabushiki (JP) | 1989-06-06 | — | — | US | disclosed |
| CN-86108331-A | The halogenated radioactive small molecule of labelled protein | — | 1987-11-04 | — | — | CN | disclosed |
| EP-0203764-A2 | Radiohalogenated small molecules for protein labeling | NEORX CORPORATION (US) | 1986-12-03 | — | — | EP | disclosed |
| US-4070484-A | Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same | KISSEI PHARMACEUTICAL CO., LTD. (JA) | 1978-01-24 | — | — | US | disclosed |
| US-4026896-A | ANTIALLERGENS | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) | 1977-05-31 | — | — | US | disclosed |
| US-3940422-A | ANTIALLERGEN | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (JA) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885KEAP1 534/4885 |
| US-20220194909-A1 | DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) | HSD11B1, HSD11B2, CYP11B1 | FFAR1 695/4885FFAR4 1638/4885KEAP1 1504/4885 |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | FFAR1 79/4885FFAR4 119/4885KEAP1 3721/4885 |
| US-12304894-B2 | Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) | HSD11B1, HSD11B2, HSD17B1 | FFAR1 623/4885FFAR4 1493/4885KEAP1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.